<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Dabigatran reduces <z:hpo ids='HP_0001297'>stroke</z:hpo> in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Pulmonary veins (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PVs</z:e>) and left atrium (LA) play a critical role in the pathophysiology of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the effects of thrombin, blood clot solution, and dabigatran on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PVs</z:e> and LA </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Conventional microelectrodes were used to record the action potentials in isolated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and LA preparations before and after the administration of thrombin or blood clot solution in control and dabigatran-treated rabbits </plain></SENT>
<SENT sid="4" pm="."><plain>Thrombin (0.01, 0.1, and 1 unit/mL), respectively, reduced the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (n=6) spontaneous beating rates from 1.9±0.2 to 1.7±0.2, 1.6±0.2, and 1.4±0.3 Hz (P=0.046) </plain></SENT>
<SENT sid="5" pm="."><plain>Blood clot solution (0.5% and 5.0%), respectively, reduced the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (n=5) spontaneous beating rates from 2.0±0.4 to 1.8±0.4 and 1.3±0.3 Hz (P=0.044) </plain></SENT>
<SENT sid="6" pm="."><plain>Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5.0%) increased LA diastolic tension and the resting membrane potential with decreased action potential duration and contractility </plain></SENT>
<SENT sid="7" pm="."><plain>Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5%) induced delayed after depolarization and burst firing in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PVs</z:e>, but not in LA </plain></SENT>
<SENT sid="8" pm="."><plain>N(G)-<z:chebi fb="13" ids="29785">nitro</z:chebi>-l-arginine <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (100 μmol/L) or a protease-activated receptor type 1 blocker (BMS 200261, 1 μmol/L) attenuated the effects of thrombin and blood clot solution in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PVs</z:e> and LA </plain></SENT>
<SENT sid="9" pm="."><plain>Dabigatran-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PVs</z:e> had slower spontaneous activity (1.1±0.1 Hz; n=10; P=0.0001 versus control) </plain></SENT>
<SENT sid="10" pm="."><plain>Their electrophysiological characteristics were not changed by thrombin (1 unit/mL) and blood clot solution (5%) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Thrombin modulates <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and LA electric and mechanical characteristics, which were blocked by dabigatran </plain></SENT>
</text></document>